<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04519710</url>
  </required_header>
  <id_info>
    <org_study_id>CREPATS 009</org_study_id>
    <nct_id>NCT04519710</nct_id>
  </id_info>
  <brief_title>Specific Anti-HBV Vaccine Response After Vaccination in Patients Requiring Anti-CD20 Monoclonal Antibodies</brief_title>
  <acronym>HepB20</acronym>
  <official_title>Pilot, Interventional Study of the Specific Anti-HBV Vaccine Response After Vaccination in Patients Requiring Anti-CD20 Monoclonal Antibodies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Vaccination coverage against HBV in France is around 30% in the adult population. Treatment&#xD;
      with anti-CD20 is associated with a risk of reactivation of hepatitis B or acute or fulminant&#xD;
      hepatitis in first-infected patients. HBV vaccination is recommended as before any anti-CD20&#xD;
      treatment in unimmunized patients.&#xD;
&#xD;
      However, there is no recommendation on which vaccination regimen to choose in patients on&#xD;
      immunosuppressants / corticosteroids or with inflammatory or autoimmune disease.&#xD;
&#xD;
      For patients who have a need for rapid immunosuppressive therapy, the use of a standard&#xD;
      vaccination schedule (D0, M1, M6) would be responsible for a loss of chance vis-à-vis the&#xD;
      underlying disease with a delay of more than 6 months to start treatment with anti-CD20. An&#xD;
      accelerated regimen (D0, D7, D21 and M12) allows healthy adults to obtain very rapid vaccine&#xD;
      protection between 77 and 90.8%. The accelerated regimen can also be considered on a&#xD;
      case-by-case basis in those adults with neurological pathologies, systemic vasculitis or&#xD;
      autoimmune disease and who need to receive anti-CD20 antibodies if the combination of&#xD;
      injections over a short period is likely to promote immunization.&#xD;
&#xD;
      The advantage of the accelerated regimen is to obtain 4 weeks, after the third dose of&#xD;
      vaccine, anti-HBs antibodies at a protective level (&gt; 10 IU / L) in approximately 77 to 90.8%&#xD;
      of patients and in the general population. The booster injection at 12 months is essential&#xD;
      for long-term protection.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An accelerated regimen allows healthy adults to obtain vaccine protection very quickly. The&#xD;
      accelerated regimen can also be considered on a case-by-case basis in those adults with&#xD;
      neurological pathologies, systemic vasculitis or autoimmune disease requiring an anti-CD20&#xD;
      monoclonal antibody if the combination of injections over a short period is likely to promote&#xD;
      immunization.&#xD;
&#xD;
      The aim of this pilot, interventional study is to evaluate the anti-HBV vaccine response&#xD;
      measured by the level of anti-HBs antibodies greater than 10 IU / l after vaccination in&#xD;
      patients to receive treatment with anti-CD20.&#xD;
&#xD;
      Evaluation of the specific anti-HBV vaccine response, measured by the level of anti-HBs&#xD;
      antibodies greater than 10 IU / l at M2, M6 and M13 in patients having received a regimen&#xD;
      accelerated by Engerix B 20 µg (D0, D7, J21), then recall 12 months later. Anti-CD20 drugs&#xD;
      should be started at least 1 month after the first 3 injections for neurological pathologies&#xD;
      and after the first 2 injections for vasculitis and autoimmune diseases (scheme linked to the&#xD;
      underlying pathology with the need for rapid treatment with anti -CD20 in these pathologies).&#xD;
&#xD;
      Follow-up of 3 parallel cohorts of patients seronegative for hepatitis B virus (HBV):&#xD;
&#xD;
        -  1 cohort followed for multiple sclerosis or another inflammatory neurological disease&#xD;
           (group 1)&#xD;
&#xD;
        -  the cohort followed for systemic vasculitis (group 2)&#xD;
&#xD;
        -  1 cohort followed for an autoimmune disease (RA, Lupus, etc.) (group 3) to receive&#xD;
           treatment with anti-CD20 (rituximab or ocrelizumab) and to be vaccinated against&#xD;
           hepatitis B.&#xD;
&#xD;
      The patients will be followed for a period of 13 months after the start of the vaccination.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 15, 2020</start_date>
  <completion_date type="Anticipated">October 15, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 15, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measure of the specific anti-HBV vaccine response, assessed by the level of anti-HBs antibodies greater than 10 IU / l at M2, M6 and M13</measure>
    <time_frame>13 months</time_frame>
    <description>regimen accelerated by Engerix B 20 µg (D0, D7, D21), then recall 12 months later&#xD;
regimen accelerated by Engerix B 20 µg (D0, D7, D21), then recall 12 months later regimen accelerated by HBV vaccine 20 µg (D0, D7, D21), then recall 12 months later</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>HBV</condition>
  <arm_group>
    <arm_group_label>multiple sclerosis or other inflammatory neurological disease</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HBV negative</description>
  </arm_group>
  <arm_group>
    <arm_group_label>systemic vasculitis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HBV negative</description>
  </arm_group>
  <arm_group>
    <arm_group_label>an autoimmune disease</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HBV negative</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>o receive treatment with anti-CD20 (rituximab or ocrelizumab) and to be vaccinated against hepatitis B</intervention_name>
    <description>to receive treatment with anti-CD20 (rituximab or ocrelizumab) and to be vaccinated against hepatitis B</description>
    <arm_group_label>an autoimmune disease</arm_group_label>
    <arm_group_label>multiple sclerosis or other inflammatory neurological disease</arm_group_label>
    <arm_group_label>systemic vasculitis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients over 18 years old&#xD;
&#xD;
          -  Multiple sclerosis or other known neurological disease (group 1), systemic vasculitis&#xD;
             (group 2) or autoimmune disease (group 3)&#xD;
&#xD;
          -  Decision on treatment with anti-CD20 (rituximab or ocrelizumab)&#xD;
&#xD;
          -  Free and informed consent, oral&#xD;
&#xD;
          -  Negative hepatitis B serology.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous hepatitis B vaccination&#xD;
&#xD;
          -  Major disability&#xD;
&#xD;
          -  Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>valérie Pourcher, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pitie-Salpetriere Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yasmine Dudoit</last_name>
    <phone>33142164181</phone>
    <email>yasmine.dudoit@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Valérie Pourcher, MD</last_name>
    <phone>33142160142</phone>
    <email>valerie.pourcher@aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Valérie POURCHER</name>
      <address>
        <city>Paris</city>
        <state>Ile De France</state>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yasmine Dudoit</last_name>
      <phone>33142164181</phone>
      <email>yasmine.dudoit@aphp.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>August 17, 2020</study_first_submitted>
  <study_first_submitted_qc>August 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 20, 2020</study_first_posted>
  <last_update_submitted>February 2, 2021</last_update_submitted>
  <last_update_submitted_qc>February 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Ocrelizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

